Comparison of the effects of gemigliptin and dapagliflozin on glycaemic variability in type 2 diabetes: A randomized, open-label, active-controlled, 12-week study (STABLE II study).

Soo Heon KwakYou Cheol HwangJong Chul WonJi Cheol BaeHyun Jin KimSunghwan SuhEun Young LeeSubin LeeSang-Yong KimJae Hyeon Kim

Published in: Diabetes, obesity & metabolism (2019)

Compared to dapagliflozin, gemigliptin significantly improved glycaemic variability, with similar glucose-lowering efficacy and safety profiles in patients with type 2 diabetes who were inadequately controlled with metformin alone or were drug naïve.

Keyphrases

type diabetes
open label
cardiovascular disease
emergency department
randomized controlled trial
insulin resistance
squamous cell carcinoma
metabolic syndrome
study protocol
glycemic control
blood glucose
adverse drug